Investigational drug · Phase 3
TR115
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TR115"
First trial start
2026
Jul 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TR115", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Clear Cell Carcinoma
- Endometrial Cancer
- Stomach Cancer Recurrent
- Urinary Bladder Cancer
- PTCL
- NK T-Cell Lymphoma
Approved drugs for the same conditions: Bladder and urothelial cancer · Endometrial cancer · Oncology · Hematology and blood cancers · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "TR115" as an intervention, largest first.
- TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell LymphomaPivotal-lookingNot yet recruiting
Tarapeutics Science Inc.Industry
NCT07639879 · 180 participants (planned) · Start Jul 30, 2026 · Primary completion Jul 30, 2029
Drug: TR115; Investigator's Choice · For: PTCL; NK T-Cell Lymphoma
Sites: Beijin, China
- TR115 in ARID1A-Mutated Advanced Solid TumorsNot yet recruiting
Tarapeutics Science Inc.Industry
NCT07793318 · 50 participants (planned) · Start Sep 20, 2026 · Primary completion May 1, 2028
Drug: TR115 · For: Ovarian Clear Cell Carcinoma; Endometrial Cancer; Stomach Cancer Recurrent and 1 more
Sites: Shanghai, China
- TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid TumorsStatus unknown
Tarapeutics Science Inc.Industry
NCT05650580 · 26 participants (planned) · Start Apr 23, 2023 · Primary completion Jul 30, 2025
Drug: TR115 · For: Non-Hodgkin's Lymphoma, Relapsed; Non-Hodgkin's Lymphoma Refractory; Advanced Solid Tumor
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ovarian Clear Cell Carcinoma
- TaxanePhase 33 trials
AstraZeneca · Breast Cancer; HER2-positive; Metastatic, Solid Tumors, Platinum-resistant Ovarian Cancer
- TulmimetostatDZR123, Tulmimetostat DL1Phase 23 trials
Novartis · Progressive Metastatic Castrate Resistant Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Advanced Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.